Northern Trust Corp Acquires 7,881 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Northern Trust Corp boosted its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 259,737 shares of the company’s stock after buying an additional 7,881 shares during the quarter. Northern Trust Corp owned approximately 0.71% of iTeos Therapeutics worth $1,995,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its position in shares of iTeos Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock worth $106,000 after purchasing an additional 1,508 shares during the period. Empowered Funds LLC boosted its position in shares of iTeos Therapeutics by 5.0% in the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after purchasing an additional 3,305 shares during the period. Peapod Lane Capital LLC bought a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $836,000. Y Intercept Hong Kong Ltd bought a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $142,000. Finally, US Bancorp DE boosted its position in shares of iTeos Therapeutics by 40.1% in the fourth quarter. US Bancorp DE now owns 16,919 shares of the company’s stock worth $130,000 after purchasing an additional 4,843 shares during the period. 97.16% of the stock is currently owned by institutional investors.

Insider Activity at iTeos Therapeutics

In other news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the sale, the insider now owns 2,108,594 shares of the company’s stock, valued at approximately $16,995,267.64. This represents a 23.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now directly owns 3,452,797 shares in the company, valued at approximately $27,829,543.82. This represents a 23.01% decrease in their position. The disclosure for this sale can be found here. 12.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ITOS. Leerink Partnrs lowered shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 14th. Raymond James set a $12.00 target price on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Wells Fargo & Company reissued an “overweight” rating and issued a $13.00 target price (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Finally, Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $17.86.

iTeos Therapeutics Stock Down 1.5%

iTeos Therapeutics stock opened at $8.56 on Monday. The company has a market cap of $327.63 million, a price-to-earnings ratio of -2.72 and a beta of 1.39. The firm’s fifty day moving average is $6.72 and its 200 day moving average is $7.38. iTeos Therapeutics, Inc. has a 52-week low of $4.80 and a 52-week high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.14. On average, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.